Request Demo
Last update 22 Sep 2025
NBL-028
Last update 22 Sep 2025
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms anti-CLDN6-CD137 BsAb, NBL 028, NBL-028 |
Target |
Action agonists, modulators |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), CLDN6 modulators(Claudin 6 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with NBL-028NCT06223256
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of NBL-028 in Patients With Advanced Solid Tumors
100 Clinical Results associated with NBL-028
Login to view more data
100 Translational Medicine associated with NBL-028
Login to view more data
100 Patents (Medical) associated with NBL-028
Login to view more data
100 Deals associated with NBL-028
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 08 Mar 2024 | |
| CLDN6-positive Solid Tumors | IND Approval | China | 24 Oct 2023 | |
| Stomach Cancer | IND Approval | China | 24 Oct 2023 | |
| Endometrial Carcinoma | IND Approval | United States | 18 Aug 2023 | |
| Non-Small Cell Lung Cancer | IND Approval | United States | 18 Aug 2023 | |
| Ovarian Cancer | IND Approval | United States | 18 Aug 2023 | |
| Testicular Neoplasms | IND Approval | United States | 18 Aug 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free